Cytokinetics (CYTK) EBIT (2016 - 2025)
Historic EBIT for Cytokinetics (CYTK) over the last 16 years, with Q4 2024 value amounting to -$139.0 million.
- Cytokinetics' EBIT fell 912.12% to -$139.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$536.2 million, marking a year-over-year decrease of 806.99%. This contributed to the annual value of -$536.2 million for FY2024, which is 806.99% down from last year.
- As of Q4 2024, Cytokinetics' EBIT stood at -$139.0 million, which was down 912.12% from -$140.8 million recorded in Q3 2024.
- Cytokinetics' EBIT's 5-year high stood at $5.2 million during Q3 2020, with a 5-year trough of -$140.8 million in Q3 2024.
- For the 5-year period, Cytokinetics' EBIT averaged around -$81.8 million, with its median value being -$93.1 million (2022).
- Per our database at Business Quant, Cytokinetics' EBIT skyrocketed by 12166.59% in 2020 and then plummeted by 143489.58% in 2021.
- Cytokinetics' EBIT (Quarter) stood at -$36.4 million in 2020, then soared by 40.39% to -$21.7 million in 2021, then crashed by 485.28% to -$127.0 million in 2022, then dropped by 0.31% to -$127.4 million in 2023, then decreased by 9.12% to -$139.0 million in 2024.
- Its EBIT stands at -$139.0 million for Q4 2024, versus -$140.8 million for Q3 2024 and -$130.2 million for Q2 2024.